Results 51 to 60 of about 6,976 (207)

MOLNUPIRAVIR DAN NIRMATRELVIR/RITONAVIR SEBAGAI TERAPI ORAL COVID-19 [PDF]

, 2022
COVID-19 merupakan penyakit infeksi yang disebabkan virus SARS-CoV-2 yang dideklarasikan sebagai pandemik global pada tanggal 11 Maret 2020. COVID-19 dapat berakibat fatal hingga menyebabkan kematian, sehingga diperlukan penanganan yang serius. Obat-obat
Raharjo, Sofyan Budi, Angelina, Emanuela
core   +1 more source

MOLNUPIRAVIR AS A PROMISING AGENT AGAINST COVID-19: A REVIEW

, 2022
Coronaviruses can cause illness in people all around the world. They typically cause respiratory infections ranging from the common cold to more serious diseases like middleeast respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS ...
Sajjad Husain Ansari, Nandre pratik, Asif Ansari
core   +1 more source

Recent Advances in Virus–Host Interactions, Antiviral Bioactive Compounds, and Breeding for Disease Resistance of Porcine Epidemic Diarrhea Virus

Animal Research and One Health, EarlyView.
Basic research on the PEDV infection cycle and virus–host interactions advances the development of anti‐PEDV drugs and disease‐resistant breeding and helps strengthen disease prevention and control while reducing economic losses in the swine industry.
Heyong Wu, Aosi Qi, Shuyu Zhong, Haozhen Du, Shimeng Guo, Hongsheng Ouyang, Hongming Yuan, Daxin Pang, Zicong Xie   +8 more
wiley   +1 more source

Molnupiravir in unvaccinated patients with COVID-19 [PDF]

Drug and Therapeutics Bulletin, 2022
Abstract Overview of: Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients. NEJM. 2021;doi:10.1056/NEJMoa2116044 [Epub ahead of print 16 Dec 2021].
openaire   +2 more sources

Molnupiravir. Portuguese

, 2021
Title from PDF caption (viewed on January 4, 2022)."OHA4029A12292021 PORTUGUESE"--Running footer.This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program.

core  

Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients

Nature Communications
Viral clearance, antibody response and the mutagenic effect of molnupiravir has not been elucidated in at-risk populations. Non-hospitalised participants within 5 days of SARS-CoV-2 symptoms randomised to receive molnupiravir (n = 253) or Usual Care (n = 
Joseph F. Standing, Laura Buggiotti, Jose Afonso Guerra-Assuncao, Maximillian Woodall, Samuel Ellis, Akosua A. Agyeman, Charles Miller, Mercy Okechukwu, Emily Kirkpatrick, Amy I. Jacobs, Charlotte A. Williams, Sunando Roy, Luz M. Martin-Bernal, Rachel Williams, Claire M. Smith, Theo Sanderson, Fiona B. Ashford, Beena Emmanuel, Zaheer M. Afzal, Adrian Shields, Alex G. Richter, Jienchi Dorward, Oghenekome Gbinigie, Oliver Van Hecke, Mark Lown, Nick Francis, Bhautesh Jani, Duncan B. Richards, Najib M. Rahman, Ly-Mee Yu, Nicholas P. B. Thomas, Nigel D. Hart, Philip Evans, Monique Andersson, Gail Hayward, Kerenza Hood, Jonathan S. Nguyen-Van-Tam, Paul Little, F. D. Richard Hobbs, Saye Khoo, Christopher Butler, David M. Lowe, Judith Breuer, PANORAMIC Virology Group   +43 more
doaj   +1 more source

Population-Based Propensity Score-Matched Analysis of Paxlovid and Molnupiravir Effectiveness in High-Risk COVID-19 Patients

International Journal of Infectious Diseases
Introduction: COVID-19 poses a severe threat to high-risk populations, such as the elderly and those with incomplete vaccination. Despite the availability of treatments like Paxlovid and Molnupiravir, their relative effectiveness in preventing severe ...
Dr Yi-hsuan Chen, Dr Cheng-Yi Lee, Dr Hao-Yuan Cheng, Mr. Yu-Neng Cheuh, Mr. Hung-Wei Kuo   +4 more
doaj   +1 more source

Differences in SARS‐CoV‐2 Antigen Persistence in Individuals With Systemic Autoimmune Rheumatic Diseases Compared to the General Population: A RECOVER‐Adult Cohort Study

Arthritis &Rheumatology, EarlyView.
Objective Individuals with systemic autoimmune rheumatic diseases (SARDs) are at risk for worse acute and post–acute COVID‐19 outcomes, though whether individuals with SARDs have longer persistence of viral antigens after COVID‐19 has not been studied.
Naomi J. Patel, Zoe Swank, Jiaqi Wang, Xiaosong Wang, Lauren A. O'Keeffe, Madison Negron, Liya S. Getachew, Louise L. Hansen, Grace Qian, Alene A. Saavedra, Kevin T. Mueller, Natalie A. Davis, Kathleen M. M. Vanni, Sandria Savage, Julie S. Lam, Zachary S. Wallace, David R. Walt, Jeffrey A. Sparks, on behalf of RECOVER‐Adult   +18 more
wiley   +1 more source

Molnupiravir. Marshallese

, 2021
Title from PDF caption (viewed on January 4, 2022)."OHA4029A12292021 MARSHALLESE"--Running footer.This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program. It is for informational purposes and

core  

Regulatory harmonization: Evolution, globalization and future directions

British Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm, Elaine Y. L. Blair, Christine Y. Lu   +2 more
wiley   +1 more source